Juvenile Dermatomyositis

Published on 06/06/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2445 times

27 Juvenile Dermatomyositis

Juvenile dermatomyositis (JDMS) is the most common inflammatory myositis during childhood, accounting for more than 80% of cases. Endothelial injury of the capillaries, venules, and small arteries of the muscle, skin, and gastrointestinal tract characterize JDMS. It is a distinct disease from adult-onset dermatomyositis because it is not associated with malignancy and tends to remit after several years.

Clinical Presentation

JDMS is a rare inflammatory myopathy with an incidence of two to four cases per million per year in children ages 16 years and younger. The mean age of onset is 7 years. However, there is a bimodal distribution with peaks at 2 to 5 years and 12 to 13 years. It is more common in girls than boys by a ratio of 2 : 1. There is no racial predominance.

Cutaneous Features

Dermatomyositis has several classic cutaneous findings (Figure 27-1). Gottron’s papules are erythematous, raised, scaling plaques on the dorsal surface of the knuckles, elbows, and knees that are present in more than 90% of children at the time of diagnosis. Gottron’s papules are frequently confused with severe eczema if JDMS is not suspected. The classic heliotrope rash is a violaceous discoloration of the eyelids with associated eyelid edema; this is present in approximately 80% of children at diagnosis. About 40% of children also have a prominent erythematous malar rash. This rash can be ulcerative, cross the nasolabial folds, and extend onto the forehead. Raynaud’s phenomenon (Figure 27-2) and associated nailfold capillary changes are seen in up to 80% of patients. Nailfold changes are characterized by proximal nailfold erythema, capillary dilatation, tortuosity, or dropout. The measured density of capillaries per millimeter may be a useful tool for monitoring clinical activity. Skin ulcerations reflect significant vasculopathy of the skin and may be a sign of internal organ vasculopathy. Ulcerative skin lesions are associated with more severe disease and worse prognosis.

Calcinosis, or calcium deposition in the skin and subcutaneous tissues, occurs in up to 40% of patients within a few years of diagnosis. Risk factors for the development of calcinosis include delayed diagnosis or treatment, TNF-α-308a genotype, and an age younger than 5 years at the time of diagnosis. Calcinosis may regress after disease remission, but complete resolution may take years. The calcinosis associated with JDMS occurs in five distinct patterns: (1) superficial calcinosis on the extremities that does not interfere with function and often regresses spontaneously; (2) deep tumoral muscle calcification in the proximal muscle groups that may interfere with joint motion, may ulcerate, and may require surgical debridement; (3) diffuse and painful calcinosis along myofascial planes that limits joint motion; (4) mixed forms of the former three types; and (5) extensive exoskeleton-like calcium deposits that result in severe functional limitations.

Other less common skin manifestations associated with JDMS are “mechanics’ hands” (thickening of the margins of the palms and radial surfaces of the hands), the shawl sign (macular erythema on the posterior neck and shoulders), the V sign (macular erythema on the anterior neck and chest), and poikiloderma vasculare atrophicans (circumscribed violaceous erythema with associated telangiectasia, hypopigmentation or hyperpigmentation, and superficial atrophy). The scalp may also be involved with seborrhea-like scaling, atrophy, and alopecia. Lipodystrophy is often underappreciated and may be present in 20% to 50% of children; it may be associated with insulin resistance, decreased glucose tolerance, acanthosis nigricans, and elevated triglycerides.

Musculoskeletal Features

Classic JDMS is manifested by symmetric, proximal muscle weakness especially in the neck, hip flexors, and abdominal wall (Figure 27-3). Targeted muscle testing is necessary because children are often able to compensate well for their weaknesses. Children may have functional limitations at the time of presentation secondary to muscle involvement. For example, affected children may report problems with brushing or washing their hair, climbing stairs, and standing from a seated position (Gower’s sign). Dysphonia, difficulty swallowing, dysphagia, and reflux of food into the nasopharynx may be present due to weakness of the palate, cricopharyngeal muscles, and upper esophagus. Rarely, the myocardium can be involved. Joint contractures may be present as a result of muscle shortening. Muscle tenderness may also be a prominent feature.

Amyopathic JDMS has the cutaneous manifestations of JDMS in the absence of clinically apparent muscle disease. Often, imaging by magnetic resonance imaging (MRI) and detailed muscle testing reveals subtle subclinical disease in these cases.

Differential Diagnosis

The diagnosis of JDMS is relatively straightforward in the presence of the characteristic rash and symmetric proximal weakness. However, the common rashes of JDMS can mimic other diseases. Gottron’s papules can be mistaken for psoriasis or seborrheic dermatitis. Malar rash is one of the diagnostic criteria for systemic lupus erythematosus (SLE); however, in contrast to JDMS, the malar rash associated with SLE does not cross the nasolabial folds. Dermatitis, pityriasis rubra pilaris, sunburn, and other sun-induced eruptions may also mimic the rashes of JDMS. Nailfold capillary changes and Raynaud’s phenomenon can be seen with systemic scleroderma, mixed connective tissue disease, CREST syndrome (calcinosis, Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias), and SLE. Juvenile polymyositis presents with similar proximal muscle weakness but lacks cutaneous manifestations.

In the absence of cutaneous manifestations, JDMS can be difficult to distinguish from other causes of muscle weakness, such as muscular dystrophy, metabolic myopathies, and infectious myositis. Muscle tenderness helps to distinguish myositis from myopathy secondary to metabolic and genetic conditions. Myositis can also be a manifestation of other connective tissue diseases such as SLE, systemic scleroderma, and mixed connective tissue disease. Lesions of the brain, spinal cord, anterior horn cell, lower motor neuron, and neuromuscular junction may also present with muscle weakness.

Evaluation and Management

JDMS is defined by the presence of characteristic skin findings plus three of the following: symmetric proximal muscle weakness, elevation of muscle enzymes, typical electromyogram (EMG) changes, and perifascicular atrophy and necrosis on muscle biopsy. To evaluate weakness, the following muscle enzymes should be measured: alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), aldolase, and creatine kinase (CK). All five enzymes should be checked because it is common for only a few to be elevated. CK levels are typically the first to increase and are usually five to 20 times the normal value; if CK levels are very high, then alternate diagnoses, such as rhabdomyolysis and muscular dystrophy, should be considered. EMG and muscle biopsy are invasive and painful diagnostic procedures reserved for the cases that are more difficult to diagnose. If subclinical myositis is suspected, MRI and ultrasonography are alternate sensitive methods to detect myositis. ANA is often elevated in patients with JDMS, but its significance is uncertain. All patients should have myositis-specific antibodies sent at the time of diagnosis because they may help predict the clinical course and direct therapy: anti-Jo-1 is associated with lung disease, anti-Mi-2 is associated with a good prognosis and response to therapy, and anti-SRP is associated with a poor prognosis and response to therapy. A swallowing study should be performed if neck flexor weakness is present.

Treatment with high-dose systemic corticosteroids is the mainstay of therapy. Typically, corticosteroids are started at high doses (2 mg/kg/d) and weaned slowly over several months. Steroid-sparing agents, such as methotrexate and cyclosporin A, are frequently initiated at the time of diagnosis. Intravenous immunoglobulin is particularly helpful for myositis and skin lesions that are not responsive to initial treatment with corticosteroids. Hydroxychloroquine is a mainstay of therapy in most patients and can help with skin manifestations; however, it takes about 3 months to reach steady state in the blood and for its effects to be seen. Cyclophosphamide is reserved for patients with severe, life-threatening disease. Quinacrine and topical tacrolimus are secondary options for skin manifestations. It is critical to avoid sun exposure because ultraviolet light exacerbates skin and muscle disease. If the esophagus is involved, patients may need nasogastric tube feeding temporarily.